Bayer’s Supreme Court Relief Is Only Half the Story; The Other Half Is Debt and a Pending Settlement
28.06.2026 - 15:23:28 | boerse-global.de
A 7-2 ruling from the U.S. Supreme Court on June 25, 2026, has reshaped the legal landscape for Bayer, sending its shares soaring 23.27 percent in a single week to close at €46.61 on Friday. Yet for all the euphoria, the company’s balance sheet remains a heavy anchor — one that no single judgment can lift.
The decision in the Durnell case makes clear that states cannot impose their own cancer warning requirements on glyphosate products as long as the Environmental Protection Agency does not mandate such a label. Federal law preempts state law. That effectively cuts off a major avenue for future Roundup lawsuits, but it does nothing to resolve the ongoing class-action settlement that has been hanging in limbo for months.
That settlement, known as King v. Monsanto, carries a price tag of up to $7.25 billion, to be paid in declining instalments over as long as 21 years. Bayer has already set aside €11.8 billion in provisions for litigation. The final judicial sign-off was supposed to come in June, but U.S. District Judge Henry E. Autrey sent the case back to a Missouri court, pushing the next critical hearing to July 9, 2026. Until that date arrives, the precise financial liability remains uncertain.
Should investors sell immediately? Or is it worth buying Bayer?
Beyond the courtroom, the company is trying to inject fresh momentum into its drug pipeline. The FDA approved its contrast agent Gadoquatran in June, while the EMA is weighing Asundexian. A new alliance with California-based Iambic Therapeutics aims to harness artificial intelligence for small-molecule drug discovery, potentially shaving years off the decade-long, $2.6 billion development cycle typical of traditional research. Those moves are meant to offset patent expirations that have already eaten into pharmaceutical revenue.
Still, the operational numbers paint a sobering picture. Bayer’s net financial debt stood at €32.5 billion at the end of the first quarter. Free cash flow was negative €2.3 billion, and the company expects around €5 billion in litigation-related cash outflows this year alone. Group revenue slipped to €45.6 billion last year as currency headwinds erased what little organic growth existed. The management has left the door open to a capital increase — a prospect that would dilute existing shareholders and pressure the stock.
On the charts, the rally has taken the relative strength index to 80.6, deep into overbought territory. The stock now trades 27.4 percent above its 200-day moving average, a spread that historically has preceded consolidation. With annualized volatility at 57.83 percent, Bayer remains a high-risk play. A pullback toward the 50-day moving average at €37.93 cannot be ruled out if sentiment sours or if the Missouri hearing throws up a surprise. Support in the €40 to €42.50 range would offer the first line of defence against a deeper correction.
Chief executive Bill Anderson has said he wants to significantly reduce the U.S. litigation overhang by year-end. The Supreme Court ruling marks a major step in that direction, but it is not the final act. The July 9 hearing in Missouri will determine whether the $7.25 billion settlement receives judicial blessing or becomes the next source of uncertainty. If the judge gives the deal the green light, the risk premium could compress further, opening a path toward the 52-week high of €49.93. If complications arise, the focus will snap back to the balance sheet — and to the nagging question of whether Bayer can close its legal chapter without breaking its financial spine.
Ad
Bayer Stock: New Analysis - 28 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
